Categories
Archives
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- March 2010
- February 2010
- January 2010
< Back to Press Releases
Monthly Archives: November 2014
‘Utter neglect’ of rheumatic heart disease revealed by results from global study
Rheumatic heart disease (RHD) – the most common acquired heart disease in children in many countries of the world – is being neglected and poorly treated, according to new findings from the Global Rheumatic Heart Disease Registry (the REMEDY study), … Continue reading
Published Wednesday, November 26th, 2014 at 12:05 am
Posted in Cardiology
Early results of new drug, ASP8273, show response in Japanese patients with treatment-resistant non-small cell lung cancer
Barcelona, Spain: In a second presentation looking at new ways of treating non-small cell lung cancer (NSCLC) that has both the EGFR and T790M mutations, researchers told the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, … Continue reading
Three drugs may be better than one for certain patients with advanced colorectal cancer
Barcelona, Spain: Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to … Continue reading
Early results show response to new drug in patients with lymphomas and advanced solid tumours
Barcelona, Spain: Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumours have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial. Preliminary results from the trial were presented … Continue reading
Published Thursday, November 20th, 2014 at 12:01 am
Posted in Cancer
Researchers pioneer new approach to treating HPV-related cervical cancer
Barcelona, Spain: A drug that is already well established as a treatment for infection of the retina in people with AIDS has been shown, for the first time, to sensitise cervical cancer to chemotherapy and radiotherapy without an increase in … Continue reading
Published Thursday, November 20th, 2014 at 12:01 am
Posted in Cancer
Researchers identify biological indicator of response to new ovarian cancer drug
Barcelona, Spain: Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib. Results of clinical trials have shown that women with tumours that are sensitive to platinum-based … Continue reading
Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib
Barcelona, Spain: A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in … Continue reading
Patients with advanced papillary kidney cancer respond well to a combination of two existing anti-cancer drugs
Barcelona, Spain: Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. Dr Ramaprasad Srinivasan, head … Continue reading
Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer
Galeterone shows activity in a variant form of castration-resistant prostate cancer
Barcelona, Spain: Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate … Continue reading
Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer
First demonstration of anti-cancer activity for AG-120, an inhibitor of the IDH1 mutation, in patients with advanced leukaemia
Barcelona, Spain: A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced … Continue reading
Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer